In NSCLC, MET mutations in the TK domain are rare and mainly emerge as an acquired resistance mechanism to MET tyrosine kinase inhibitors or as a resistance mechanism to combinational therapy with EGFR and MET TKI in MET exon 14 skipping positive patients or EGFR-mutant and MET gene amplification positive patients. The gene discussed is MET; the disease is non-small cell lung carcinoma.